| | | 深圳瑞华泰薄膜科技股份有限公司 关于"瑞科转债"预计满足转股价格修正条件 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、可转债发行上市概况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意深圳瑞华 泰薄膜科技股份有限公司向不特定对象发行可转换公司债券注册的批复》（证监 许可〔2022〕1546 号）同意注册，深圳瑞华泰薄膜科技股份有限公司（以下简 称"公司"）于 2022 年 8 月 18 日向不特定对象共计发行 430 万张可转换公司债 券（以下简称"可转债"），每张面值为人民币 100 元，按面值发行，本次发行总 额为人民币 43,000.00 万元，可转债期限为自发行之日起六年。 上述方案须经出席会议的股东所持表决权的三分之二以上通过方可实施。股 东大会进行表决时，持有本次发行的可转债的股东应当回避。修正后的转股价格 应不低于本次股东大会召开日前二十个交易日公司股票交易均价和前一个交易 日公司股票交易均价。 2、修正程序 如公司决定向下修正转股价格时，公司将在上交所网站（w ...

Core Viewpoint - Haichuang Pharmaceutical Co., Ltd. has launched its self-developed innovative anti-cancer drug, Dihydro-Enzalutamide soft capsule, marking a significant milestone in its development journey [2][3] Group 1: Product Launch and Clinical Significance - Dihydro-Enzalutamide soft capsule is recognized as a new type of androgen receptor antagonist (ARi) and has shown significant clinical value, particularly in treating metastatic castration-resistant prostate cancer (mCRPC) [2] - Clinical studies indicate that Dihydro-Enzalutamide significantly improves disease progression and survival rates while demonstrating excellent safety profiles, with no adverse events such as falls or seizures reported [2] - Experts suggest that Dihydro-Enzalutamide has the potential to be moved forward in treatment protocols for metastatic hormone-sensitive prostate cancer (mHSPC) [2][3] Group 2: Company Development and Future Plans - The inauguration of Haichuang Pharmaceutical's headquarters and the rapid nationwide supply of Dihydro-Enzalutamide signify a critical leap from research innovation to industrial empowerment [3] - The company focuses on developing innovative drugs for cancer and metabolic diseases and plans to accelerate the global rollout of multiple anti-cancer and metabolic disease drugs [3] - Haichuang Pharmaceutical's chairman emphasized the importance of patient-centered research and the collective effort of employees and partners in achieving this milestone [3]

| | | 深圳瑞华泰薄膜科技股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本季度转股情况：深圳瑞华泰薄膜科技股份有限公司（以下简称"公司"） 向不特定对象发行可转换公司债券"瑞科转债"自 2023 年 2 月 24 日起可转换为 公司股份，自 2025 年 4 月 1 日至 2025 年 6 月 30 日期间，未有"瑞科转债"转 换为公司股票，转股数量为 0 股。 1 18 日至 2028 年 8 月 17 日。 累计转股情况：截至 2025 年 6 月 30 日，"瑞科转债"累计共有人民币 7,000 元已转换为公司股票，累计转股数量为 224 股，占"瑞科转债"转股前公 司已发行股份总额的 0.000124%。 未转股可转债情况：截至 2025 年 6 月 30 日，"瑞科转债"尚未转股的可 转债金额为人民币 429,993,000 元，占"瑞科转债"发行总量的 99.998372%。 一、可转债发行上市概况 经中国证券监督管理委员会《关于同意深圳瑞华泰薄 ...

证券代码：688323 证券简称：瑞华泰 债券代码：118018 债券简称：瑞科转债 深圳瑞华泰薄膜科技股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告 （2024年度） 债券受托管理人 （深圳市罗湖区红岭中路 1012 号国信证券大厦 16-26 层） 二〇二五年六月 1 重要声明 本报告依据《可转换公司债券管理办法》（以下简称"《管理办法》"）、《深 圳瑞华泰薄膜科技股份有限公司（发行人）与国信证券股份有限公司（受托管理 人）签订的科创板向不特定对象发行可转换公司债券之受托管理协议》（以下简 称"《受托管理协议》"）、《深圳瑞华泰薄膜科技股份有限公司向不特定对象发 行可转换公司债券募集说明书》（以下简称"《募集说明书》"）、《深圳瑞华泰 薄膜科技股份有限公司 2024 年年度报告》等相关公开信息披露文件、第三方中 介机构出具的专业意见等，由本次债券受托管理人国信证券股份有限公司（以下 简称"国信证券"）编制。国信证券对本报告中所包含的从上述文件中引述内容 和信息未进行独立验证，也不就该等引述内容和信息的真实性、准确性和完整性 做出任何保证或承担任何责任。 本报告不构成对投资者进行或不进行某项 ...

深圳瑞华泰薄膜科技股份有限公司 关于获得政府补助的公告 | 证券代码：688323 | 证券简称：瑞华泰 | 公告编号：2025-028 | | --- | --- | --- | | 转债代码：118018 | 转债简称：瑞科转债 | | 特此公告。 深圳瑞华泰薄膜科技股份有限公司董事会 2025 年 6 月 27 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获得政府补助的基本情况 深圳瑞华泰薄膜科技股份有限公司（以下简称"公司"）全资子公司嘉兴瑞 华泰薄膜技术有限公司于近日收到政府补助款人民币 3,189 万元，属于与资产相 关的政府补助。 二、补助的类型及对上市公司的影响 根据《企业会计准则第 16 号——政府补助》的有关规定，公司获得的上述 政府补助属于与资产相关的政府补助。上述政府补助未经审计，具体的会计处理 及对公司损益的影响最终以审计机构年度审计确认后的结果为准，敬请投资者注 意投资风险。 1 ...

Core Viewpoint - Hecotech Pharmaceuticals has received approval for its core product, Deutetrabenazine capsules, marking the company's first commercialized product after years of operating with zero drug revenue [2][3]. Group 1: Product Approval and Market Potential - Deutetrabenazine capsules are approved for treating metastatic castration-resistant prostate cancer (mCRPC) in adult patients who have not previously received novel androgen receptor inhibitors [3]. - The drug is the first deuterated mechanism innovation in the prostate cancer field and the first domestic innovative drug approved for this indication [3]. - According to GLOBOCAN 2022, there were 1.467 million new prostate cancer cases globally in 2022, with 134,000 new cases reported in China [3]. Group 2: Company Financials and Historical Context - Prior to the approval of Deutetrabenazine, Hecotech Pharmaceuticals had maintained a "zero drug revenue" status, resulting in cumulative losses of 1.703 billion yuan from 2019 to 2024 [4]. - The company is accelerating its commercialization process and has established a GMP-compliant R&D production base in Chengdu, along with a professional marketing team [4]. Group 3: Competitive Landscape - Deutetrabenazine is a deuterated version of enzalutamide, which was originally developed by Astellas and Medivation and has generated over $4 billion in global sales by 2019 [5]. - Enzalutamide's sales reached $5.67 billion in 2024, making it a significant revenue source for Astellas [5]. - Several domestic companies have developed generic versions of enzalutamide, with competition expected to intensify as the patent expires in 2026 [5].

Group 1 - The company will participate in the 2024 Annual Performance Presentation for the Advanced Petrochemical Chemical New Materials Industry on May 27, 2025, from 15:00 to 17:00 [2][3] - The meeting will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online text interaction format [2][3] - Key personnel attending the meeting include the Vice Chairman and General Manager, Mr. Tang Changdan, Independent Director, Mr. Huang Hua, Chief Financial Officer, Mr. Huang Zehua, and Secretary of the Board, Ms. Li Tao [2] Group 2 - Investors can log in to the Shanghai Stock Exchange Roadshow Center to participate in the performance presentation and ask questions [3] - Questions can be submitted from May 20, 2025, to May 26, 2025, before 16:00 through the Roadshow Center website or via the company's email [3] - After the meeting, investors can view the presentation details and main content on the Shanghai Stock Exchange Roadshow Center [3]

| | | 深圳瑞华泰薄膜科技股份有限公司 关于参加 2024 年度先进石化化工新材料行业集体业 绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 27 日(星期二)下午 15:00-17:00 深圳瑞华泰薄膜科技股份有限公司（以下简称"公司"）已于 2025 年 3 月 22 日在上海证券交易所网站（http://www.sse.com.cn/）披露公司 2024 年年度报 告，为便于广大投资者更全面深入地了解公司 2024 年年度经营成果、财务状况， 公司计划于 2025 年 5 月 27 日(星期二)下午 15:00-17:00 参加 2024 年度科创板先 进石化化工新材料行业集体业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次业绩说明会以网络文字互动形式召开，公司将针对 2024 年年度的经营 1 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地 ...

Group 1 - Yitong Century won a bid for a communication engineering construction service project from China Mobile, with a total bid amount of 228 million yuan (including tax) [1] - Zhiyuan New Energy plans to repurchase shares worth between 33 million and 66 million yuan, with a maximum repurchase price of 22.00 yuan per share [1] - GAC Group reported April automobile sales of 116,400 units, a year-on-year decrease of 12.66% [2] - JAC Motors reported April automobile sales of 30,764 units, a year-on-year decrease of 3.55% [3] Group 2 - Fosun Pharma's subsidiary received FDA approval for a clinical trial of a live biotherapeutic product aimed at treating androgenetic alopecia [4] - Liangxin Co. obtained multiple patent certificates, including 2 invention patents and 32 utility model patents [5] - Sainuo Medical's two products received medical device registration certificates in Mexico and Ecuador [5] - Huayu Pharmaceutical's two products received marketing approvals in France and Spain [6] Group 3 - Shengnong Development reported April sales revenue of 1.533 billion yuan, a year-on-year increase of 0.68% [6] - Hasi Lian's potassium chloride and sodium chloride injection passed the consistency evaluation [7] - Shapuaisi received approval for a supplemental application for levofloxacin eye drops [9] - Tianyu Biological reported April sales revenue of 59.32 million yuan from pig sales [10] Group 4 - *ST Weihai was pre-awarded a project worth 108 million yuan [12] - Luoniushan reported April sales revenue of 125 million yuan from pig sales, a year-on-year increase of 12.72% [13] - Minhe Co. reported April sales revenue of 68.30 million yuan from chick sales, a year-on-year increase of 0.51% [14] Group 5 - Double Ring Technology's application for a specific stock issuance was approved by the Shenzhen Stock Exchange [15] - Hualu Hengsheng plans to repurchase shares worth between 200 million and 300 million yuan [16] - Baolong Technology plans to repurchase shares worth between 100 million and 200 million yuan [17] Group 6 - Huasheng Technology's subsidiary plans to sell shares of a company for 200 million yuan [24] - *ST Gengxing's controlling shareholder plans to increase holdings worth between 30 million and 60 million yuan [25] - Ruihuatai's shareholder plans to reduce holdings by up to 1% of the company's shares [26] Group 7 - Foton Motor reported April commercial vehicle sales of 54,816 units, a year-on-year increase of 21.63% [20] - China Merchants Bank plans to invest 15 billion yuan to establish a financial asset investment company [22] - Jinchengxin plans to invest approximately 231 million USD in the Alacran copper-gold-silver mine project [23] Group 8 - Zhongji United's controlling shareholder plans to reduce holdings by up to 2% of the company's shares [30] - Ningbo Huaxiang signed a strategic cooperation agreement to strengthen collaboration in various areas [31] - SMIC reported a net profit of 1.356 billion yuan for Q1 2025, a year-on-year increase of 166.5% [32] Group 9 - FAW Fuwi received a project notification to develop seat products for a luxury brand, with a total sales amount expected to be 1.39 billion yuan [33] - Huakang Clean won a bid for a purification project worth 64.425 million yuan [34] - Lihua Co. reported April sales revenue of 1.125 billion yuan from chicken sales [35]

中国经济网北京5月9日讯瑞华泰(688323.SH)昨晚披露股东减持股份计划公告称，公司于近日收到股东 国投高科技投资有限公司(以下简称"国投高科")出具的《关于股份减持计划的告知函》。 因自身经营发展需要，公司股东国投高科拟通过集中竞价方式减持数量合计不超过1,800,002股(不超过 公司总股本比例1.0000%)。本次减持计划自公告披露之日起15个交易日之后的3个月内实施。上述股份 减持价格按市场价格确定。 | 股东名称 | 国投高科技投资有限公司 | | --- | --- | | 计划减持数量 | 不超过:1,800,002 股 | | 计划减持比例 | 不超过:1.0000% | | 减持方式及对应减持数量 | 集中竞价减持,不超过:1,800,002 股 | | 减持期间 | 2025年5月30日~2025年8月29日 | | 拟减持股份来源 | IPO 前取得 | | 拟减持原因 | 自身经营发展需要 | 瑞华泰上市发行费用为5033.09万元，其中保荐机构国信证券、联席主承销商中信建投证券获得保荐及 承销费用3420万元。 2022年9月9日，瑞华泰发布向不特定对象发行可转换公司债券上市公告 ...